The downgrade from Buy to Hold by a major analyst firm like Jefferies suggests a less optimistic view on Deciphera Pharmaceuticals' future stock performance. The slight reduction in the price target further indicates concerns about the company's valuation or growth prospects. Such analyst actions can lead to a negative short-term impact on the stock price as market sentiment adjusts to the new recommendations.